全文获取类型
收费全文 | 7533篇 |
免费 | 290篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 111篇 |
妇产科学 | 51篇 |
基础医学 | 412篇 |
口腔科学 | 36篇 |
临床医学 | 509篇 |
内科学 | 1981篇 |
皮肤病学 | 15篇 |
神经病学 | 128篇 |
特种医学 | 315篇 |
外科学 | 3522篇 |
综合类 | 65篇 |
预防医学 | 86篇 |
眼科学 | 21篇 |
药学 | 96篇 |
1篇 | |
中国医学 | 7篇 |
肿瘤学 | 475篇 |
出版年
2024年 | 3篇 |
2023年 | 606篇 |
2022年 | 713篇 |
2021年 | 874篇 |
2020年 | 721篇 |
2019年 | 343篇 |
2018年 | 349篇 |
2017年 | 259篇 |
2016年 | 278篇 |
2015年 | 297篇 |
2014年 | 708篇 |
2013年 | 572篇 |
2012年 | 259篇 |
2011年 | 96篇 |
2010年 | 349篇 |
2009年 | 325篇 |
2008年 | 91篇 |
2007年 | 115篇 |
2006年 | 121篇 |
2005年 | 59篇 |
2004年 | 53篇 |
2003年 | 39篇 |
2002年 | 71篇 |
2001年 | 52篇 |
2000年 | 49篇 |
1999年 | 79篇 |
1998年 | 89篇 |
1997年 | 25篇 |
1996年 | 47篇 |
1995年 | 32篇 |
1994年 | 34篇 |
1993年 | 16篇 |
1992年 | 9篇 |
1991年 | 8篇 |
1990年 | 9篇 |
1989年 | 10篇 |
1988年 | 13篇 |
1987年 | 10篇 |
1986年 | 12篇 |
1985年 | 5篇 |
1984年 | 9篇 |
1983年 | 6篇 |
1982年 | 3篇 |
1981年 | 5篇 |
1980年 | 4篇 |
1978年 | 7篇 |
1976年 | 2篇 |
1975年 | 3篇 |
1972年 | 3篇 |
1970年 | 3篇 |
排序方式: 共有7848条查询结果,搜索用时 15 毫秒
981.
982.
983.
984.
985.
《Transfusion and apheresis science》2022,61(4):103418
AimTo determine whether convalescent angiotensin (1?7) peptide replacement therapy with plasma (peptide plasma) transfusion can be beneficial in the treatment of critically ill patients with severe coronavirus 2 (SARS-CoV-2) infection.Study designCase series of 9 critically ill patients with laboratory-confirmed COVID-19 who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment.Peptide plasma: Plasma with angiotensin (1?7) content 8–10 times higher than healthy plasma donors was obtained from suitable donors. Peptide plasma transfusion was applied to 9 patients whose clinical status and/or laboratory profile deteriorated and who needed intensive care for 2 days.ResultsIn our COVID-19 cases, favipiravir, low molecular weight heparin treatment, which is included in the treatment protocol of the ministry of health, was started. Nine patients with oxygen saturation of 93% and below despite nasal oxygen support, whose clinical and/or laboratory deteriorated, were identified. The youngest of the cases was 36 years old, and the oldest patient was 85 years old. 6 of the 9 cases had male gender. 3 cases had been smoking for more than 10 years. 4 cases had at least one chronic disease.In all of our cases, SARS CoV2 lung involvement was bilateral and peptide plasma therapy was administered in cases when oxygen saturation was 93% and below despite nasal oxygen support of 5 liters/minute and above, and intensive care was required. Although it was not reflected in the laboratory parameters in the early period, 8 patients whose saturations improved with treatment were discharged without the need for intensive care. However, a similar response was not obtained in one case. Oxygen requirement increased gradually and, he died in intensive care process. An increase of the platelet count was observed in all cases following the peptide plasma treatment.ConclusionIn this preliminary case series of 9 critically ill patients with COVID-19, administration of plasma containing angiotensin (1?7) was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials. 相似文献
986.
《The Annals of thoracic surgery》2023,115(2):394-395
987.
ObjectivesTo evaluate the use of temporary-permanent pacemaker (TPP) in patients with right bundle branch block (RBBB) undergoing transcatheter aortic valve replacement (TAVR). We also sought to identify key predictors of permanent pacemaker (PPM) within 30 days of TAVR in this population.BackgroundRBBB is a well-recognized risk factor for PPM post TAVR. TPP provides stable transient pacing and reduces the need for critical care beds.MethodsThis is a retrospective chart review of 371 patients who underwent TAVR at our institution. All patients with pre-existing RBBB had TPP placed prior to TAVR (n = 37). The primary outcome was the need for critical care beds. Multivariate logistic regression analysis was performed to identify predictors of PPM within 30 days of TAVR.Results67 patients required PPM within 30 days of TAVR, and 56 implanted before discharge. 51% (19 out of 37) of TPP group required PPM before discharge compared to 11% (37 out of 334) of No TPP (p < 0.001), yet TPP group spent significantly fewer hours in a critical care bed (19 vs 28 h, p = 0.01). Length of membranous septum (LMS) <8.49 mm was the strongest independent predictor of PPM within 30 days of TAVR (RAUC of 0.80, Sensitivity 0.7 and Specificity 0.8) and 98% of patients with LMS < 7 mm required PPM within 30 days.ConclusionTPP-TAVR is a well-defined multidisciplinary protocol that reduces the need for critical care beds in patients with pre-existing RBBB referred for TAVR. Additionally, LMS is the strongest predictor of PPM implantation in this population.Condensed abstract (100 words)This study evaluated the use of temporary-permanent pacemakers (TPP) in patients with right bundle branch block (RBBB) undergoing transcatheter aortic valve replacement (TAVR). TPP-TAVR provided stable pacing allowing for early mobilization and reduced the need for critical care beds. Multivariate logistic regression analysis identified length of membranous septum (LMS) <8.49 mm in patients with RBBB as the strongest independent predictor of PPM need within 30 days of TAVR. 98% of patients with RBBB and LMS < 7 mm required PPM at 30 days regardless of other characteristics including valve type and size. 相似文献
988.
989.
990.